Crescent Biopharma (FRA:C68) Payments of Debt: €0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C68 Crescent Biopharma Inc FRA:C68
18 GF Score
Price €12.40
! 2 Warning Signs
View Full Analysis

What is Crescent Biopharma Payments of Debt?

Crescent Biopharma FRA:C68 -3.88% 18 Payments of Debt is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:C68 with a GF Score™ of 18/100. The stock has 2 warning signs investors should review.

Crescent Biopharma's Payments of Debt for the three months ended in Mar. 2026 was €0.00 Mil.

Crescent Biopharma's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Crescent Biopharma Payments of Debt Related Terms

Crescent Biopharma Payments of Debt Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma Payments of Debt Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
Payments of Debt
0.00 0.00

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
FRA:C68
18GF Score
Crescent Biopharma Inc FRA:C68
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of €0.00 Mil mean?
Crescent Biopharma (FRA:C68) has a Payments of Debt of €0.00 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Crescent Biopharma and its competitors.
Is Crescent Biopharma's Payments of Debt too high?
Crescent Biopharma's current Payments of Debt is €0.00 Mil. Overall, Crescent Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's Payments of Debt compare to KYTX and ZURA?
Crescent Biopharma's Payments of Debt of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Crescent Biopharma and its competitors. Crescent Biopharma's current Payments of Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (FRA:C68) has a current Payments of Debt of €0.00 Mil. The current Payments of Debt is €0.00 Mil. Crescent Biopharma's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Crescent Biopharma (FRA:C68), the current Payments of Debt is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescent Biopharma Business Description

Other Exchanges CBIO:USA
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
18GF Score

Get the complete analysis for FRA:C68

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.40
Price